108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
不同给药途径和给药方式下细胞外囊泡治疗支气管肺发育不良的效果分析
Authors Xu W, Chen S, Liang T, Kang L, Zheng Q, Yang Y, Guo L, Liu J, Zhang R, Dong W
Received 4 April 2025
Accepted for publication 26 August 2025
Published 22 September 2025 Volume 2025:20 Pages 11617—11645
DOI https://doi.org/10.2147/IJN.S530819
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Jie Huang
Wanting Xu,1– 3 Siyu Chen,1– 3 Ting Liang,1– 3 Lan Kang,1– 3 Qinxin Zheng,1– 3 Yan Yang,1– 3 Ling Guo,3 Jing Liu,3 Rong Zhang,1– 3 Wenbin Dong1– 3
1Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 2Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 3Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China
Correspondence: Rong Zhang, Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China, Email zhangrong9604@163.com Wenbin Dong, Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China, Email dongwenbin2000@163.com
Abstract: Extracellular vesicles (EVs) are emerging as nanoscale, cell-free therapeutics for bronchopulmonary dysplasia (BPD), a chronic lung disease in premature infants characterized by underdeveloped alveoli and abnormal blood vessel formation. This review exhibits how different EV delivery methods influence therapeutic effects in BPD. Intra-tracheal administration of EVs enables localized pulmonary delivery, which may improve treatment efficiency via reducing inflammation and promoting lung development. Intravenous delivery provides systemic anti-inflammatory effects requiring higher doses because of lung’s blood vessel barriers. Intraperitoneal administration requires higher dosages to produce comparable effects and shows lower drug accumulation in the lungs. Intragastric administration often results in poor absorption due to the digestive environment. The distribution of EVs in the body is largely dependent on delivery methods. Nebulized and tracheal administrated EVs primarily concentrate in the lungs, whereas intravenous EVs tend to distribute in the liver and spleen. Mechanistically, EVs reduce oxidative stress and cell damage by influencing important biological pathways like TGF-β 1/Smad3 and PTEN/PI3K/Akt. Although previous studies in neonatal animal models demonstrated that EVs are safe and promising, clinical translation of EVs requires standardized production, optimized dosage, non-invasive administration method, and long-term safety verification. Future efforts are suggested to focus on neonate targeting, biomarker-guided clinical trials of EVs in treating BPD.
Plain Language Summary: Premature infants with bronchopulmonary dysplasia (BPD) experience chronic lung impairment, characterized by impaired lung development and persistent inflammation. Current therapeutic options for these infants are limited and may be associated with adverse effects. Extracellular vesicles are tiny particles released by cells, which have demonstrated potential in treating BPD in preclinical studies. This review compares different methods of delivering EVs, including intratracheal inhalation, intravenous injection, intraperitoneal injection, and oral-intragastric routes. Inhalation of EVs targets the lungs of affected infants, reducing inflammation and supporting alveolar development. Intraperitoneal delivery is less effective than intravenous injection, which requires larger doses but has anti-inflammatory effects throughout the body. Oral administration of EVs poses challenges for infants due to intestinal degradation. By transporting molecules (eg proteins, miRNAs) that guard against damaging pathways and restore lung tissue. In spite of promising preclinical results, further research is required to examine EV production, dosages, and safety before clinical use in premature infants. Future researches are suggested to focus on developing EVs for non-invasive targeted delivery, pharmacokinetic modeling specific to neonates, and biomarker-driven trials to treat BPD.
Keywords: extracellular vesicle, bronchopulmonary dysplasia, drug delivery, administration routes
1Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 2Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 3Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China
Correspondence: Rong Zhang, Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China, Email zhangrong9604@163.com Wenbin Dong, Division of Neonatology, Department of Pediatrics, the Affiliated Hospital of Southwest Medical University, Luzhou, China; Department of Perinatology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Sichuan Clinical Research Center for Birth Defects, Luzhou, People’s Republic of China, Email dongwenbin2000@163.com
Abstract: Extracellular vesicles (EVs) are emerging as nanoscale, cell-free therapeutics for bronchopulmonary dysplasia (BPD), a chronic lung disease in premature infants characterized by underdeveloped alveoli and abnormal blood vessel formation. This review exhibits how different EV delivery methods influence therapeutic effects in BPD. Intra-tracheal administration of EVs enables localized pulmonary delivery, which may improve treatment efficiency via reducing inflammation and promoting lung development. Intravenous delivery provides systemic anti-inflammatory effects requiring higher doses because of lung’s blood vessel barriers. Intraperitoneal administration requires higher dosages to produce comparable effects and shows lower drug accumulation in the lungs. Intragastric administration often results in poor absorption due to the digestive environment. The distribution of EVs in the body is largely dependent on delivery methods. Nebulized and tracheal administrated EVs primarily concentrate in the lungs, whereas intravenous EVs tend to distribute in the liver and spleen. Mechanistically, EVs reduce oxidative stress and cell damage by influencing important biological pathways like TGF-β 1/Smad3 and PTEN/PI3K/Akt. Although previous studies in neonatal animal models demonstrated that EVs are safe and promising, clinical translation of EVs requires standardized production, optimized dosage, non-invasive administration method, and long-term safety verification. Future efforts are suggested to focus on neonate targeting, biomarker-guided clinical trials of EVs in treating BPD.
Plain Language Summary: Premature infants with bronchopulmonary dysplasia (BPD) experience chronic lung impairment, characterized by impaired lung development and persistent inflammation. Current therapeutic options for these infants are limited and may be associated with adverse effects. Extracellular vesicles are tiny particles released by cells, which have demonstrated potential in treating BPD in preclinical studies. This review compares different methods of delivering EVs, including intratracheal inhalation, intravenous injection, intraperitoneal injection, and oral-intragastric routes. Inhalation of EVs targets the lungs of affected infants, reducing inflammation and supporting alveolar development. Intraperitoneal delivery is less effective than intravenous injection, which requires larger doses but has anti-inflammatory effects throughout the body. Oral administration of EVs poses challenges for infants due to intestinal degradation. By transporting molecules (eg proteins, miRNAs) that guard against damaging pathways and restore lung tissue. In spite of promising preclinical results, further research is required to examine EV production, dosages, and safety before clinical use in premature infants. Future researches are suggested to focus on developing EVs for non-invasive targeted delivery, pharmacokinetic modeling specific to neonates, and biomarker-driven trials to treat BPD.
Keywords: extracellular vesicle, bronchopulmonary dysplasia, drug delivery, administration routes